detail
*It has been translated using AI
As Hanmi Pharmaceutical has achieved the feat of exporting up to $2.3 billion (about 3.1723 trillion won) worth of new obesity drug candidates to Genentech, a subsidiary of Global Big Pharma Roche, attention is being paid to the obesity treatment pipeline of domestic pharmaceutical and bio companies aiming for “Next Hanmi.”
There are three main tracks. It is a direction to improve the inconvenience and side effects of existing glucagon-like peptide (GLP-1) injections such as Hugo Bee and Mountaineer. Currently, a once-a-week injection is given every two weeks, or a new mechanism is used to develop a drug that is taken instead of an injection.
◆ Reduce side effects such as nausea and vomiting
According to the industry on the 24th, HKINOEN is conducting phase 3 clinical trials in Korea of “Eknoglutide” with its own technology and aims to complete medication within this year. It is characterized by a so-called ‘bias action’ mechanism that selectively activates only specific signals within the cell.
It blocks signals that cause side effects of gastrointestinal disorders such as nausea and vomiting, which are chronic disadvantages of obesity drugs, and maximizes only signals that produce weight loss effects to increase drug effectiveness and significantly reduce side effects. In particular, phase 2 clinical trials abroad are focusing on proving excellent effects by securing direct comparison data with Semaglutide (product name Hugo Bee), a global blockbuster obesity drug.
JW Pharmaceutical has applied for a Phase 3 clinical trial plan for its long-lasting GLP-1 agonist “Bofanglutide,” which is administered once every two weeks. The plan is to design the drug to be slowly released from the body to reduce the hassle of patients who need to be injected daily or weekly and dramatically increase medication compliance.
There is also an active challenge to pioneer a niche market by developing ‘obesity drugs’ instead of injections. Ildong Pharmaceutical Group recently completed the phase 1 clinical trial of ID110521156, an obesity drug taken through Unovia, a subsidiary specializing in new drug development. As most of the obesity treatment market is centered on injections, the plan is to target the global market with low-molecular-weight compounds that can be easily taken at home.
◆ Competition for innovation to reduce patient discomfort
Next-generation research that combines completely new genetic technology is also accelerating. Olyx, a new drug development biotechnology company, is developing an obesity treatment using RNA interference technology. It fundamentally prevents the expression of certain genes responsible for fat metabolism. It’s the critical limit of existing treatmentsIts strength is that it minimizes phenomenon and muscle loss side effects, and it confirmed a significant weight loss effect in preclinical primates. Dong-A ST is conducting phase 1 clinical trials of the double agent ‘DA-1726’, which promotes energy consumption while suppressing appetite. Daewoong Pharmaceutical builds early obesity pipelines from various angles with a microneedle patch type in the form of a band-aid that eliminates stabbing pain.
An official from the pharmaceutical industry said, “The paradigm of the global obesity treatment market is moving quickly beyond simple weight loss to how conveniently patients can maintain a high-quality life. As a signal of Hanmi Pharmaceutical’s achievement, Big Pharma’s interest in domestic pharmaceutical bio companies with original technology will increase further.”
[Reporter Go Jaewon]
#
Most Read News
- 1
Photos from actor Lee Jun-young’s training camp, after he enlisted in the Republic of Korea Army (RO
- 2
The story of a rice cake restaurant owner in his 30s who decided to close the business due to employ
2026.08.23 15:14
- 3
The body of Jang Mi-ran (37), who has been missing for more than three months since May, has been fo
5 Hours ago
- 4
As the domestic stock market continues its roller-coaster trend, which has recently seen a sharp dec
7 Hours ago
- 5
After Samsung Electronics and SK Hynix recently announced their shareholder return policy, there are
3 Hours ago
- 6<img src="https://healthylife7.com/wp-content/uploads/2026/08/rcv.NEWS1_.NEWS1_.20260408.2026-04-08T141628_1007843908_SOCIETY_I_T1.jpg" alt=""Pension is more beneficial than children who are filial with their mouths."How Senior Citizens' Income jumped 80% in 10 years“>
It was found that the living structure of the elderly who relied on their children’s allowance is ra
8 Hours ago
- 7
Amid growing opposition from non-resident single-home owners over the government’s recently announce
2 Hours ago
- 8
As Samsung Electronics announced the scale of its shareholder returns this year and its future divid
4 Hours ago
- 9
People who have faithfully paid the national pension premium for more than 10 years every month whil
2026.08.23 13:58
- 10
The labor union of the Financial Supervisory Service has taken collective action against the governm
2 Hours ago
![Seventeen's DxS: "This Is a Time to Become Stronger and Deeper" [Photo Shoot]](https://healthylife7.com/wp-content/uploads/2026/08/A12133181_35_20260821144945.png)
DxS of the group Seventeen revealed a more mature mood through a fashion magazine cover.On the 21st
Singer and actress Bae Suzy has shared an update on her recent life.On the 20th, Bae Suzy posted sev
Lia, a member of the group ITZY, showed off her bikini figure.On the 21st, Lia posted several photos
![Dayoung, a Solo Artist Who Encompasses Music, Visuals, and Performance [Photo]](https://healthylife7.com/wp-content/uploads/2026/08/A12132147_35_20260820133449.png)
Dayoung of Cosmic Girls (WJSN) showed an even more defined presence as a solo artist.On the 20th, Be
